DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff Et Al US006528521B2 (12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff et al. (45) Date of Patent: Mar. 4, 2003 (54) TREATMENT OF ANTI-DEPRESSION DRUG- 5,756.483. A 5/1998 Merkus ....................... 514/58 INDUCED SEXUAL DYSFUNCTION WITH 5,770,606 A 6/1998 El-Rashidy et al. ........ 514/284 APOMORPHINE 5,866,164 A 2/1999 Kuczynski et al. ......... 424/472 5,897.864. A 4/1999 Cohen ..................... 424/195.1 5,939,094. A 8/1999 Durif et al. ................. 424/448 (75) Inventors: 3. P slot, NSS). 5,945,117 A 8/1999 El-Rashidy et al. ........ 424/430 (73) Assignee: Tap Pharmaceutical Products, Inc., OTHER PUBLICATIONS Lake Forest, IL (US) Marketletter of Jul. 17, 1995 (abstract).* (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Wilson, E.K., Chemical & Engineering News, 76(26), pp. 29 U.S.C. 154(b) by 0 days. (Jun. 29, 1998). (21) Appl. No.: 09/993,782 * cited by examiner (22) Filed: Nov. 14, 2001 O O Primary Examiner Phyllis G. Spivack (65) Prior Publication Data (74) Attorney, Agent, or Firm- Wood, Phillips, Katz, Clark US 2002/0115683 A1 Aug. 22, 2002 & Mortimer Related U.S. Application Data (57) ABSTRACT (60) Provisional application No. 60/249,031, filed on Nov. 15, A method for treating Sexual dysfunction that is caused by 2000. anti-depressant medication in a patient in need of Such (51) Int. Cl. .............................................. A61K 31/473 treatment, comprising administering a therapeutically effec (52) U.S. Cl. ....................................................... 5141284 tive amount of apomorphine, or a pharmaceutically accept (58) Field of Search .......................................... 514,284 able salt thereof to said patient, is disclosed. The method may be utilized for patients taking anti-depressants Such as (56) References Cited tricyclic anti-depressants, monamine oxidase inhibitors or Serotonin Selective reuptake inhibitors. U.S. PATENT DOCUMENTS 4,521,421. A 6/1985 Foreman ..................... 514/267 9 Claims, No Drawings US 6,528,521 B2 1 2 TREATMENT OF ANTI-DEPRESSION DRUG SUMMARY OF THE INVENTION INDUCED SEXUAL DYSFUNCTION WITH The present invention is directed to a method of treating APOMORPHINE Sexual dysfunction in a patient taking anti-depressant medi cation in need of Such treatment comprising administering a This application claims the benefit of Provisional appli therapeutically effective amount of apomorphine or a phar cation Ser. No. 60/249,031, filed Nov. 15, 2000. maceutically acceptable Salt thereof to Said patient. The FIELD OF THE INVENTION anti-depressant medication may be a tricyclic anti depressant, a monamine oxidase inhibitor or a Serotonin The present invention is directed to a method for treating selective reuptake inhibitor. Preferably, the therapeutically Sexual dysfunction in a patient taking anti-depressant medi 1O effective amount of apomorphine is an amount wherein a cation in need of Such treatment comprising administering a concentration of apomorphine is attained within Said therapeutically effective amount of apomorphine or a phar patient's plasma of up to 10 nanograms per milliliter. maceutically acceptable Salt thereof to Said patient. The method may be utilized for patients taking anti-depressants If the patient is male, the therapeutically effective amount 15 may be an amount Sufficient to induce an erection adequate Such as tricyclic anti-depressants, monamine oxidase inhibi for vaginal penetration. Alternatively, if the patient is female tors or Serotonin Selective reuptake inhibitors. the therapeutically effective amount may be an amount BACKGROUND OF THE INVENTION Sufficient to induce clitoral erectogenesis and vaginal engorgement. Preferably, the therapeutically effective Depression is a chronic illness that affects people of all amount is insufficient to produce emesis. However, if larger ageS. Tricyclic antidepressants, monamine oxidase (potentially emesis-inducing) doses are required, the apo inhibitors, and Selective Serotonin reuptake inhibitors are classes of drugs which are prescribed for the treatment of morphine may be co-administered with an emesis-inhibiting depression. Tricyclic anti-depressants include imipramine amount of an anti-emetic agent. hydrochloride, imipramine pamoate, amitriptyline The anti-emetic agent may be nicotine, lobeline Sulfate, hydrochloride, desipramine hydrochloride and protriptyline 25 metoclopramide, chlorpromazine, prochlorperazine, hydrochloride. Monamine oxidase inhibitors include pipamazine, thiethylperazine, oxypendyl hydrochloride, isocarboxazid, phenelZine Sulfate and tranylcypromine Sul domperidone, ondansetron, buclizine hydrochloride, cycliz fate. Of the various classes of anti-depressants currently ine hydrochloride, dimenhydrinate, Scopolamine, available, the Selective Serotonin reuptake inhibitors metopimazine, trimethobenzamide, benzauinamine hydro (SSRIs) are among the most successful. chloride or diphenidol hydrochloride. SSRIs include fluoxetine, fluvoxamine, citalopram, In the method, apomorphine may administered cericlamine, femoxetine, ifoxetine, cyanodothiepin, intranasally, orally ingested, Sublingually or administered by seritraline, paroxetine and litoxetine. Anti-depressants have inhalation to the lungs. Moreover, the apomorphine may be many undesirable Side effects, Such as disturbance of Sexual administered as a pharmaceutically acceptable Salt, prefer function. Since Sexual dysfunction is common in depression 35 ably the hydrochloride salt. as part of the underlying disease, the use of a drug to treat depression which may further cause Sexual dysfunction is DETAILED DESCRIPTION OF THE particularly objectionable. INVENTION A variety of Strategies have been reported in the manage In males, the form of Sexual dysfunction is erectile ment of SSRI-induced Sexual dysfunction, including waiting 40 dysfunction. A normal erection occurs as a result of a for tolerance to develop, dosage reduction, drug holidayS, coordinated vascular event in the penis. This is usually Substitution of another anti-depressant drug, and various triggered neurally and consists of vasodilation and Smooth augmentation Strategies (addition of another drug) with muscle relaxation in the penis and its Supplying arterial 5-HT, 5-HT, and C adrenergic receptor antagonists, vessels. Arterial inflow causes enlargement of the Substance 5-HT1A and dopamine receptor agonists and phosphodi 45 of the corpora cavemosa. Venous outflow is trapped by this esterase enzyme inhibitors, as disclosed by Rosen et al. in J. enlargement, permitting Sustained high blood preSSures in Clin. Psychopharmacol. Vol. 19, No 1, pp.67-84. the penis Sufficient to cause rigidity. Muscles in the Augmentation Strategies may include co-treatment with perineum also assist in creating and maintaining penile cy proheptadine, bethanecol, yohimbine, amantadine, 50 rigidity. Erection may be induced centrally in the nervous alprazolam, chlordiazepoxide, clonazepam, diazepam or System by Sexual thoughts or fantasy, and is usually rein lorazepam according to Forman et al., “Drug-induced infer forced locally by reflex mechanisms. Erectile mechanics are tility and Sexual Dysfunction” in Textbook of Erectile substantially similar in the female for the clitoris. Dysfunction, Oxford: Isis Medical Media Ltd, 1999, pp. Impotence or male erectile dysfunction is defined as the 40–43; co-treatment with Ginkgo Biloba as disclosed in U.S. 55 inability to achieve and Sustain an erection Sufficient for Pat. No. 5,897,864; or co-treatment with sidenafil, according intercourse. Impotence in any given case can result from to Fava et al., “An Open Trial of Oral Sildenafil in psychological disturbances (psychogenic), from physiologi Antidepressant-Induced Sexual Dysfunction”, Psychother. cal abnormalities in general (organic), from neurological Psychosom., 1998, 328-331. disturbances (neurogenic), hormonal deficiencies Nevertheless, there is still a need for effective medications 60 (endocrine) or from a combination of the foregoing. Impo which can be used to treat Sexual dysfunction in patients tence may be hormonal, congenital, Vascular or partial taking anti-depressants. ability, among others. It is therefore an object of the present invention to provide These descriptions are not exact, however. There is cur a method for the treatment of Sexual dysfunction in patients rently no Standardized method of diagnosis or treatment. AS taking anti-depressants, to treat the condition potentially 65 used herein, psychogenic impotence is defined as functional caused by the depression and exacerbated by the anti impotence with no apparent overwhelming organic basis. It depressant. may be characterized by an inability to have an erection in US 6,528,521 B2 3 4 response to Some Stimuli (e.g., masturbation, spontaneous diamyl Sulfates, long chain halides Such as decyl, lauryl, nocturnal, spontaneous early morning, video erotica, etc.) myristyl and Stearyl chlorides, bromides and iodides, aryla but not others (e.g., partner or spousal attention). lkyl halides like benzyl and phenethyl bromides and others. Females also can have Sexual dysfunction that increases Water or oil-soluble or dispersible products are thereby with age and is associated with the presence of vascular risk obtained. Examples of acids which can be employed to form factors and onset of menopause. Some of the vascular and pharmaceutically acceptable acid addition Salts include Such muscular mechanisms that contribute to penile erection in inorganic acids
Load more

Recommended publications
  • Postoperative Vomiting: a Review and Present Status of Treatment
    POSTOPERATIVE VOMITING: A REVIEW ~ND ~?RESENT STATUS OF TREATMENT* L. E. SI2vlONSEN, M.D., C.NI., and S. L. VANDEWAjTER,M.D., r.R.c.r. (c.) t POSTOPERATIVE VO~vlITING remains one of the most I frequent complications en- countered by the anaesthetist. Although considered no|more than a nuisance complication, it can, in certain cases, contribute to more ~lSan just discomfort for the patient; it can threaten his very life either immediately through aspiration, or later by serious loss bf fluids and electrolytes. It cap also add considerable strain on some operation wounds. After Wang and Boxison 1 further delineated the vomit ng centre in 1952, most of the succeeding research and investigation into the ~ontrol of vomiting has centred about those drugs that have a depressant actio 1 on the chemoreceptor trigger zone (C.T.Z.). Out of these investigations have c ~me much valuable and interesting data which the anaesthetist may use as additio ns to his ever-expanding resources to provide safety and comfort to the surgical patient. THE VOMXTn~OCENTaE Neurophysiologists have long accepted the existence of a vomiting centre. Located in the medulla in the solitary tract and the dgrsal part of the lateral reticular formation, it lies in close relationship to ma:ay other centres whose functions are associated with the vomiting act such ts salivation, spasmodic respiratory movements, and forced inspiration. ~ Lying lorsolateral to the vagal nuclei and close to the vomiting centre in the area pos :rema of thefloor of the fourth ventricle is an accessory vomiting centre which Ihas been designated as the C.T.Z.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury
    DMD Fast Forward. Published on January 24, 2014 as DOI: 10.1124/dmd.113.056267 DMD FastThis Forward.article has not Published been copyedited on and January formatted. 24, The 2014final version as doi:10.1124/dmd.113.056267 may differ from this version. DMD #56267 High daily dose and being a substrate of Cytochrome P450 enzymes are two important predictors of drug-induced liver injury Ke Yu, Xingchao Geng, Minjun Chen, Jie Zhang, Bingshun Wang, Katarina Ilic and Weida Tong Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Downloaded from US Food and Drug Administration, Jefferson, AR, USA (K.Y., M.C., J.Z., W.T) National Center for Safety Evaluation of Drugs, National Institute for Food and Drug Control, China's State Food and Drug Administration, Beijing, China (X.G.) dmd.aspetjournals.org Department of Biostatistics, Shanghai Jiao Tong University School of Medicine, Shanghai, China (B.W.) Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia (K.I.) at ASPET Journals on September 24, 2021 1 Copyright 2014 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on January 24, 2014 as DOI: 10.1124/dmd.113.056267 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56267 Running title: Two important predictors for drug-induced liver injury Corresponding authors: Katarina Ilic, Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, 450 Vojvode Stepe, Belgrade 11221, Serbia. E-mail address: [email protected]. Weida Tong, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Road, Jefferson, Downloaded from AR 72079, USA.
    [Show full text]
  • The Action of Thiethylperazihe Torecan®), a New Anti-Emetic, Compared
    TH,'E ACTION OFf THIETHYLPERAZI!~Ei: ~ITO!~ECANr A NE'~( ANTI''-- EMETIC, COMPARED,' WITH:". PER[P:NHE' i ' q[AZINE ' ( TRILAFON|:'1 L TR~METHOBENZAMIDE (TIGAN| AND[A PI.ACE~O IN THE" suPPRESSION OF POSTANAESTHETI~NAIUSEN AND V()MITING IAN E. PtrnICIS, M.B., B.S., ~.F.A..I~.C.S.O POSTa_Na_ESTH~TIC VOMITING has been ~shown ~0 b(l" i~ffffeneed ]~y a varie]ty of factors, and it is therefore unlikely that any a~i-ergetie drug will be completely effective and without side-effects in all patients. In[the absence of any ele~r-eut superiority of one drug over another,-the physi4ian naust exercise a choicK selecting a drug with minimum side-effects but maximum anti-emetic effect. This choice can only be made on the basis of ieontrolled studies of effectir and side-effects, since clinical impressions can be nlost misleading.~ Malay ~igents can be shown to have an anti-emetic effect wl~n e0mpared I with a placebo (e.g., atropine) 1 but they may not be clinically us,~fuI as anfi-erneties. If new drug can be shown to have an effect equal to ~or better than a drug whi, .a has proven highly effective against a strong clinica,l challenge, then it is likeb that the new agent will be clinically useful. Thiethylperazine (Toreean| is a phenothiazin Which possesses to a very marked degree the anti-emetic activity common to all drugs, of this group, while the other group activities of lowering bk od pressure,~=.potentiatign of narcotics and barbil~urates, and extrapyramidal et feets, are minimized.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al
    USO09526704B2 (12) United States Patent (10) Patent No.: US 9,526,704 B2 BOSse et al. (45) Date of Patent: *Dec. 27, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR A6IR 9/24 (2006.01) TREATING OR PREVENTING PAN A69/20 (2006.01) (52) U.S. Cl. (71) Applicant: LOCL Pharma, Inc., Las Vegas, NV CPC ............. A61K 9/209 (2013.01); A61 K9/2013 (US) (2013.01); A61 K9/2054 (2013.01); A61 K 3 1/167 (2013.01); A61K 31/485 (2013.01); (72) Inventors: Paul Bosse, Jupiter, FL (US); John A61K 3.1/5415 (2013.01) Ameling, Jupiter, FL (US); Bernard (58) Field of Classification Search Schachtel, Jupiter, FL (US); Ray CPC A61K 2300/00; A61K 31/167; A61K 31/485; Takigiku, Loveland, OH (US) A61K 3.1/5415: A61 K9/2054: A61 K 9/209 (73) Assignee: LOCL PHARMA, INC., Las Vegas, See application file for complete search history. NV (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,048,526 A 8/1962 Boswell This patent is Subject to a terminal dis- 3,108,046 A 10/1963 Harbit claimer. (Continued) (21) Appl. No.: 15/206.955 FOREIGN PATENT DOCUMENTS 1-1. CA 2262267 A1 8, 1999 (22) Filed: Jul. 11, 2016 DE 102005O13726 A1 9, 2006 (65) Prior Publication Data (Continued) US 2016/0317447 A1 Nov. 3, 2O16 OTHER PUBLICATIONS Related U.S. Application Data US 8.975,271, 03/2015, Oshlack et al.
    [Show full text]
  • CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No
    US010064856B2CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No. : US 10 , 064 ,856 B2 Bosse et al. ( 45 ) Date of Patent: * Sep . 4 , 2018 ( 54 ) PHARMACEUTICAL COMPOSITIONS (52 ) U .S . CI. ??? . .. A61K 31/ 485 ( 2013 .01 ) ; A61K 9 / 209 @(71 ) Applicant : LOCL PHARMA , INC . , Las Vegas , ( 2013 . 01 ) ; A61K 9 / 2013 ( 2013 . 01 ) ; A61K NV ( US ) 9 /2027 ( 2013 .01 ) ; A61K 9 / 2054 ( 2013 .01 ) ; A61K 9 / 4808 ( 2013 .01 ) ; A61K 31 / 165 @(72 ) Inventors : Paul Bosse, Jupiter , FL (US ) ; John ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Ameling , Jupiter, FL (US ) ; Bernard 31/ 24 ( 2013 .01 ) ; A6IK 31/ 403 ( 2013 .01 ) ; Schachtel, Jupiter, FL (US ) ; Ray A61K 31/ 404 (2013 .01 ) ; A61K 31 /4196 Takigiku , Loveland , OH (US ) ( 2013 . 01 ) ; A61K 31/ 422 ( 2013 . 01 ) ; A61K 31 / 437 ( 2013 .01 ) ; A61K 31/ 454 ( 2013 .01 ) ; @( 73 ) Assignee : LOCAL PHARMA , INC ., Las Vegas , A61K 31 /515 ( 2013 . 01 ) ; A61K 31/ 522 ( 2013 . 01 ) ; A61K 31 /5415 ( 2013 .01 ) ; A61K NV (US ) 45 / 06 ( 2013 .01 ) ; A61K 9 / 0024 ( 2013 .01 ) ; @( * ) Notice : Subject to any disclaimer , the term of this A61K 9 / 0056 ( 2013 . 01 ) ; A61K 9 / 1694 patent is extended or adjusted under 35 ( 2013 . 01 ) ; A61K 9 /2086 ( 2013 . 01 ) ; A61K U . S . C . 154 (b ) by 0 days . 47 / 36 ( 2013 .01 ) (58 ) Field of Classification Search This patent is subject to a terminal dis None claimer . See application file for complete search history . ( 21 ) Appl. No .: 15 / 683, 635 ( 56 ) References Cited ( 22 ) Filed : Aug . 22, 2017 U . S . PATENT DOCUMENTS 3 ,048 , 526 A 8 / 1962 Boswell (65 ) Prior Publication Data 3 , 108 , 046 A 10 / 1963 Harbit 3 , 536 ,809 A 10 / 1970 Norman US 2017 /0348303 A1 Dec .
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]
  • Trimeprazine Tartrate (Panectyl| Diphenhy- Dramine Hce (Benadryl| Dimenhydrinate (Gravol| Dramam I Ne| and Cyiclizine Lactate (Marzine| Marazi Ne|
    THE ANTISIALOGOGUE EFFECT OF TRIMETHOBENZAMIDE HCL (TIGAN| TRIMEPRAZINE TARTRATE (PANECTYL| DIPHENHY- DRAMINE HCE (BENADRYL| DIMENHYDRINATE (GRAVOL| DRAMAM I NE| AND CYICLIZINE LACTATE (MARZINE| MARAZI NE| ALLEN B. DOBKINI~ and V. GuY CRISWICK~ IT IS DIFFICULT tO tell clinically whether an ancillary drug, which is useful in association with anaesthesia, has useful physiological eh%cts other tha.n those of its primary action unless they are studied specifically. The a ntisialogogue effects of the following drags which are used primarily ~as antihistaminics and anti-emetics are reported here. Trimethobenzctmide HCL (Tigan| is la substituted benzamide which con- tains the active substance 4-(2-dimetliylaminoethoxy)-N-(3,4,5-trimethoxy. benzoyl)-benzylamine HCL.-It is a White, odourless, crystalline powder which is water soluble (more than 50 per cent at 25 ~ C), and has a bitter taste. It has been used primarily as an anti-emetic, t Its anti-emetic effect appears to act at the chemoreceptor trigger zone, as with the phenothiazine derivatives, although its chemical structure resembles the dimethyl aminoethoxy antihistamines, such as diphenhydramine. It is not as effective in preventing vomiting caused by strong reflex visceral impulses. It does not cause,any hypnotic sedation or behavioural depression as is observed with chlorpromazine. Tigan does ~lot have the anti- histaminic or antiadrenaline effects of the phenothiazines or structuralb: related compounds. 2 Trimeprazine tartrate (Panectyl| is a iphenothiazine derivative whose anti. histaminic and anti-emetic properties exceed those of promethazine. It has only a weak antiadrenaline effect, but its spasmolytic effect exceeds that of chlorpro- mazine. The hypnotic sedative action is of the same order as promdthazine.
    [Show full text]
  • Laws of Fiji
    LAWS OF FIJI CHAPTER 115 PHARMACY AND POISONS Cap . 115 Rev. 1985 Pharmacy and Poisons 3 CHAPTER 115 PHARMACY AND POISONS TABLE OF PROVISIONS PART I-PRELIMINARY SECTION 1 . Short title 2. Interpretation 2A. Meaning of "medicine" and related expressions 2a. Certain substances or articles to be treated as medicines 3. Meaning of "sale" 4. Meaning of "adulteration" PART II-ADMINISTRATION 5. The Pharmacy and Poisons Board 6. Members of Board 7. Meetings of the Board 8. Board may summon person to attend and give evidence 9. Chairman may administer oath 10. Person failing to appear when summoned 11. Person refusing to .make oath or affirmation 12. False testimony 13. Liability of members 14. Fees 15. Power of search 16. Secretary. Inspectors 17. Persons eligible for appointment as inspectors 18. Powers of inspectors 19. Certificate of Government analyst PART III-PHARMACISTS 20. Register of Pharmacists 21. Pharmacists how registered 22. Persons eligible for registration 23. Board may direct examination of applicant 24. Registration of applicants 25 . Appeal against refusal of Board to register 26. Copy of register to be published 27. Fraudulent representation 28. Amendments may be made in register 4 Pharmacy and Poisons Cap. 115 Rev. 1985 29. Notification of change of address or death 30. Correction of register 31 . Corporate body may carry on business of pharmacist 32. Restriction on number of pharmacies 32A . Establishment of Fiji Pharmaceutical Society 32B. Objects of Fiji Pharmaceutical Society 32c . Former Fiji Pharmaceutical Society PART IV-CONDUCT OF BUSINESS AS PHARMACIST 33. Grounds of cancellation of registration 34. Removal of name from register 35.
    [Show full text]
  • Pharmacy & Poisons Act Cap
    LAWS OF FIJI REVISED 1985 CHAPTER 115 ______ PHARMACY AND POISONS ______ TABLE OF PROVISIONS ______ PART I - PRELIMINARY SECTION 1. Short title 2. Interpretation 2A. Meaning of "medicine" and related expressions 2B. Certain substances or articles to be treated as medicines 3. Meaning of "sale" 4. Meaning of "adulteration" PART II - ADMINISTRATION 5. The Pharmacy and Poisons Board 6. Members of Board 7. Meetings of the Board 8. Board may summon person to attend and give evidence 9. Chairman may administer oath 10. Person failing to appear when summoned 11. Person refusing to make oath or affirmation 12. False testimony 13. Liability of members 14. Fees 15. Power of search 16. Secretary. Inspectors 17. Persons eligible for appointment as inspectors 18. Powers of inspectors 19. Certificate of Government analyst PART III - PHARMACISTS 20. Register of Pharmacists 21. Pharmacists how registered 22. Persons eligible for registration 23. Board may direct examination of applicant 24. Registration of applicants 25. Appeal against refusal of Board to register 26. Copy of register to be published 27. Fraudulent representation 28. Amendments may be made in register 29. Notification of change of address or death 30. Correction of register 31. Corporate body may carry on business of pharmacist 32. Restriction on number of pharmacies 32A. Establishment of Fiji Pharmaceutical Society 32B. Objects of Fiji Pharmaceutical Society 32C. Former Fiji Pharmaceutical Society PART IV - CONDUCT OF BUSINESS AS PHARMACIST 33. Grounds of cancellation of registration 34. Removal of name from register 35. Surrender of certificate of registration 36. Persons other than registered pharmacists not to carry on business 37.
    [Show full text]